威尔士结直肠癌氟嘧啶治疗前DPYD基因分型的成本效果评价
该经济学评价构建决策分析模型,比较威尔士结直肠癌患者氟嘧啶处方前DPYD基因分型指导用药与按标准剂量处方的成本效果。结果显示筛查可节省成本、减少药物不良反应并增加QALY,在每QALY两万英镑阈值下具有成本效果。检测标准变异及额外变异(如c.557A>G)可进一步提高增量净健康获益。
要点
- 氟嘧啶处方前DPYD筛查可能节省成本并减少药物不良反应。
- 标准变异检测的增量净健康获益为0.0118 QALY,成本效果概率为0.96。
- 检测额外变异(含c.557A>G)可增加增量净健康获益,结果经敏感性分析稳健。
核心结论
- 氟嘧啶处方前开展DPYD筛查可能具有成本效果,可节省NHS资源并减少药物不良反应。
研究设计与样本
- 研究构建决策分析模型,比较药物基因组学指导处方(可干预变异者减量或换药)与不考虑基因状态按标准许可剂量处方的成本效果。
- 以每获得一个质量调整生命年(QALY)两万英镑为成本效果阈值评估增量净健康获益(INHB)。
- 采用概率敏感性分析、单因素敏感性分析和情景分析刻画模型不确定性并评估结果稳健性。
主要发现
- 模型显示筛查较全体患者标准剂量氟嘧啶可节省成本、减少药物不良反应并增加QALY。
- 检测c.1905+1G>A、c.1679T>G、c.2846A>T、c.1129-5923C>G和c.1236G>A的估计INHB为0.0118 QALY(95%中心范围-0.0490至0.0575),成本效果概率为0.96。
- 检测包括c.557A>G在内的额外变异可增加INHB。
- 结果在一系列敏感性分析中保持稳健。
关键数值与推荐
- 英国监管指南建议氟嘧啶类治疗前进行DPYD基因分型。
- 成本效果阈值为每QALY两万英镑。
临床怎么用
- 结直肠癌患者使用氟嘧啶前可考虑DPYD基因分型,对可干预变异者减量或选用替代药物。
- 在标准检测组合基础上以较小额外成本检测更多变异,可能进一步减少药物不良反应负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine-based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in standard DPYD testing. METHODS: Decision-analytic models were developed to compare the cost-effectiveness of pharmacogenomic-guided prescribing, where patients with actionable variants are prescribed reduced-dose fluoropyrimidines or an alternative drug, against a strategy of prescribing a standard licensed dose irrespective of genetic status. Incremental net health benefit (INHB) was assessed at a cost-effectiveness threshold of £20 000 per quality-adjusted life year (QALY) gained. Probabilistic and univariate sensitivity and scenario analyses characterized modelling uncertainty and assessed the responsiveness of the results to a range of assumptions. RESULTS: Screening prior to prescribing was modelled to be cost-saving, result in fewer adverse drug reactions and be associated with more QALYs than prescribing all patients standard dose fluoropyrimidines. Testing for c.1905+1G>A, c.1679T>G, c.2846A>T, c.1129-5923C>G and c.1236G>A was associated with an estimated INHB of 0.0118 QALYs (95% central range -0.0490, 0.0575) and 0.96 probability of being cost-effective. Screening for additional variants, including c.557A>G increased the INHB. The results were robust across a range of sensitivity analyses. CONCLUSION: DPYD screening prior to the prescription of fluoropyrimidines is likely to be a cost-effective use of National Health Service resources. Testing for additional variants at minimal additional cost has important implications for reducing the burden of adverse drug reactions and health inequalities in ethnically diverse societies.
引用
- Plumpton CO, Morgan SM, Adams RA, et al. Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based treatment for colorectal cancer in Wales. Br J Clin Pharmacol. 2026. PMID: 42171466. doi:10.1002/bcp.70617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。